Back to Trades
Total Value
$5.6M
Net $2.6M sold
Filing Date
Jul 9, 2026
3 transactions
Sales
$2.6M
3 transactions
Trade Summary
On Jul 7, 2026 through Jul 9, 2026, Delaet Ingrid, Chief Regulatory Officer, sold $5.6M of NEUROCRINE BIOSCIENCES INC (NBIX) across 3 transactions. The filing covers Common Stock and reflects net selling of $2.6M. Reported prices ranged from $103.52 to $178.72. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- NEUROCRINE BIOSCIENCES INC
- Ticker Symbol
- NBIX
- CIK
- 0000914475
Insider Information
- Name
- Delaet Ingrid
- Role
- Chief Regulatory Officer
- Location
- SAN DIEGO, CA
Filing Details
- Filing Date
- Jul 9, 2026
- Transaction Date
- Jul 7, 2026
- Accession Number
- 0001965808-26-000011
- Form Type
- 4
- Net Trading Amount
- -$2.6M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Jul 7, 2026 | Common Stock | 3,401 | $103.52 | Exercise | $352.1K |
| Jul 7, 2026 | Common Stock | 3,401 | $178.57 | Sale | $607.3K |
| Jul 8, 2026 | Common Stock | 2,737 | $103.52 | Exercise | $283.3K |
| Jul 8, 2026 | Common Stock | 2,737 | $178.54 | Sale | $488.7K |
| Jul 9, 2026 | Common Stock | 8,433 | $103.52 | Exercise | $873.0K |
| Jul 9, 2026 | Common Stock | 8,433 | $178.72 | Sale | $1.5M |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jul 7, 2026 | NBIX derivative | 3,401 | $103.52 | Exercise | $352.1K |
| Jul 8, 2026 | NBIX derivative | 2,737 | $103.52 | Exercise | $283.3K |
| Jul 9, 2026 | NBIX derivative | 8,433 | $103.52 | Exercise | $873.0K |
Want live alerts when Delaet Ingrid trades again?
Download Insider Trades to track NBIX, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- (F2)Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $178.52 to $178.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (F3)Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $178.52 to $178.59. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (F4)Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $178.52 to $179.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (F5)The option was granted February 13, 2023 and vests in 48 equal monthly installments beginning March 13, 2023.